Copyright 2016 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.
The ability to diagnose the pathology of neurodegenerative diseases in patients during life remains one of the holy grails of behavioral neurology. Considerable progress has been made over the past decade or so. We can now accurately predict the pathology—Alzheimer disease (AD) with plaques and tangles—in patients with progressive amnesia accompanied by attentional and executive deficits and followed, in turn, by aphasic and visuospatial problems. The accuracy of AD diagnoses has also been aided by the advent of ligand-based amyloid positron emission tomographic imaging, although this technique remains extremely expensive and is only available in the developing world and, even there, is not yet available in clinical practice.
Hodges JR. Pathological Diagnosis During Life in Patients With Primary Progressive Aphasia: Seeking the Holy Grail. JAMA Neurol. 2016;73(7):788–789. doi:10.1001/jamaneurol.2016.0792
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: